Nurix Therapeutics, Inc. NRIX Increase (decrease) in contract liabilities and current deferred income
Increase (decrease) in contract liabilities and current deferred income at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Nurix Therapeutics, Inc. (NRIX) reported increase (decrease) in contract liabilities and current deferred income of -$1.25M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income changed year-over-year?
- Nurix Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income increased by 87.3% year-over-year, from -$9.83M to -$1.25M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income?
- Over 2 years (2022 to 2025), Nurix Therapeutics, Inc.'s increase (decrease) in contract liabilities and current deferred income has grown at a 17.8% compound annual growth rate (CAGR), from -$26.63M to -$36.98M.